After graduating from the University of Kentucky College of Pharmacy and Gatton College of Business and Economics, Dr. Mattingly dove directly into pharmacy practice for The Kroger Company, facilitating the implementation of a new information system to more than 40 pharmacies. After completion of the pharmacy system rollout, he managed four different Kroger Pharmacy locations between 2010 and 2012 before being promoted to serve as District Pharmacy Coordinator in Carbondale, Illinois, overseeing operations for 12 pharmacies.
In 2013, Dr. Mattingly was hired to lead Indianapolis operations as general manager for a start-up long-term care company called AlixaRx, providing pharmacy services and remote automated dispensing systems to 23 skilled nursing facilities across Indiana, Kentucky, and Ohio. From 2014 to 2019, he served as an assistant professor in the Department of Pharmacy Practice & Science while concurrently completing a Doctor of Philosophy (PhD) in Health Services Research with a special focus in pharmacoeconomics. He currently serves as an associate professor in the Department of Pharmaceutical Health Services Research at the University of Maryland School of Pharmacy, where his research focus is in health economics and outcomes research with an emphasis on costs of care. In 2016, Dr. Mattingly was selected as the graduating class Teacher of the Year and in 2018 was honored with the prestigious Albert B. Prescott Pharmacy Leadership Award.
In addition to his work as a faculty member, he is currently an advisory panel member for Clinical Effectiveness and Decision Science for the Patient-Centered Outcomes Research Institute and advisor for the Maryland Department of Health Prescription Drug Monitoring Program. He also serves as an Editorial Advisory Board member for the American Journal of Pharmaceutical Education and PharmacoEconomics – Open.
Agenda: Day 1 Oct 5, 2020
Agenda: Day 2 Oct 6, 2020
Afternoon Keynote: U.S./CANADA COMPARISONS
Understanding the Nuances of Drug Pricing
The economy may be rebounding, but we will be ‘paying’ for the government’s pandemic spending for years to come. Clarify your understanding of where we stand compared to the US and other countries with respect to drug pricing. Gain insight and bring back learnings to better:
- Describe supply chain components and drug price terminology broadly, and the specifics to the Canadian market
- Identify the different pricing nuances and policies developed to address drug prices paid from different perspectives
- Re-evaluate your assumptions when it comes to price setting